Combined anti-tuberculosis drug.
Hydroxymethyl-quinoxylindioxide
Synthetic antibacterial agent, a derivative of quinoxaline. Activates the processes of peroxidation, which lead to a disruption of DNA biosynthesis and deep structural changes in the cytoplasm of microbial cells.
Has a bactericidal effect in relation to the rod of Rod Friedlander, Proteus vulgaris, Pseudomonas aeruginosa, Escherichia coli, Salmonella spp., Shigella dysenteria, Shigella boydii, Shigella flexneri, Shigella sonnei, Staphylococcus spp., Streptococcus spp., anaerobes Clostridium perfringens.
Isoniazid
Inhibits the enzymes necessary for the synthesis of mycolic acids, which are the main structural fragments of the cell walls of mycobacterium tuberculosis.
The most intensive synthesis of mycolic acids is carried out in growing cells, so isoniazid has a bactericidal action on them, and bacteriostatic action on mature cells. The high selectivity of the chemotherapeutic effect of isoniazid is due to the fact that there are no mycolic acids in the tissues of the macroorganism, as well as in other microorganisms.
In combination with hydroxymethylquinoxaline dioxide, 5 times more active against mycobacteria tuberculosis.